ASCO 2021: Fate's iPSC-derived NK cell clinical data is active

Recent popular reports from Yimaike ★ Invitation to the event2021 Oncolytic Virus Drug Development Forum is about to open in Shanghai ★ The financing has been hundreds of millions in half a year, and the oncolytic virus has entered the fast laneYimai New Observation Click on the picture and register now June 9, 2021 /Healthcare News eMedClub News/--Fate recently announced the results of a multi-dose phase I clinical trial of FT516 at the 2021 American Society of Clinical Oncology (ASCO) annual meeting held on the weekend to study FT516 as a treatment for acute myeloid leukemia Monotherapy, combined with CD20 targeting monoclonal antibody to treat advanced B-cell lymphoma (NCT04023071)
.

The results showed that FT516 was active in patients who had undergone a lot of pretreatment and was well tolerated
.

▲ Interim data from the FT516 Phase I relapsed/refractory ALL study (picture source: fate) FT516 is the company's general-purpose, ready-made natural killer (NK) cell candidate product, which is an engineered clone of induced pluripotent stem cells (iPSC) Department of development
.

FT516 is designed to maximize antibody-dependent cytotoxicity to destroy antibody-coated cancer cells
.

The clinical report showed that 8 of the 11 patients who could be studied achieved objective remission, and 6 of them achieved complete remission
.

Eight of these 11 patients had aggressive B-cell lymphoma, and four of them had previously received autologous CD19 and CAR-T cell therapy
.

 The report specifically highlighted a case of "triple-hit, high-grade B-cell lymphoma with MYC, BCL2, and BCL6 gene rearrangements
.
"
Except for autologous CD19 and CAR-T cell therapy, the trial patients were ineffective to all previous therapies
.

After the first treatment cycle of FR516, the patient achieved complete remission, all metabolically active diseases were resolved, and the size of the target lesion was reduced by 85%
.

 At the data cutoff date of March 11, the patient completed the second FT516 treatment cycle, after which the response assessment continued to show a complete response
.

➤ The emergence of iPSC-derived cell therapy The application of immune checkpoint inhibitors (ICI) has made tumor immunity and cell therapy flourish
.

However, with the deepening of research, people have found that there are many subjects who have no obvious effect on ICI treatment or who have relapsed later
.

The development of this field has encountered a bottleneck
.

However, scientists have discovered in clinical trials that adoptive transfer of NK cells has the inherent potential to overcome many of these ICI resistance mechanisms
.

NK cell treatment methods are beginning to gain attention
.

In 2018, Fate broke through technical barriers, developed FT500 and obtained FDA clinical research approval
.

This is also the first iPSC-derived cell therapy approved for research
.

FT500 will be combined with checkpoint inhibitor (ICI) for the treatment of advanced solid tumors
.

Since then, with the improvement of the induced pluripotent stem cell (iPSC) product platform and the accumulation of technology, FATE has launched a number of clinical NK cell project research
.

 For more details, please click the QR code below to read the reference materials: 1.
https:// from-lymphoma-study/YiMike has always been committed to original news reports such as cutting-edge technology, industry trends, industry insights, etc.
of bio-innovative drugs.
The high-end matrix users of all media have reached 160,000+, of which industrial users accounted for more than 50%.
Research and clinical About 30% of users, and more than 5% of users of investment institutions
.

In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.